Caris Life Sciences Announces Pricing of Initial Public Offering

Caris Life Sciences Announces Pricing of Initial Public Offering

IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the pricing of its initial public offering of 23,529,412 shares of its common stock, at a…

Enigmatig Limited Announces Pricing of Initial Public Offering

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Enigmatig Limited ("Enigmatig" or the "Company"), an international consultancy firm providing one-stop cross-border licensing solutions and related services, today announced the pricing of its initial public offering ("IPO") of 2,845,200 Class A ordinary shares at a price to the public of US$5.00 per share. The Class A ordinary shares have been approved for listing on the NYSE American Market and are e…

AI Meets Biotech — and Hedge Funds Are Buying In

An innovative health care company that describes itself as a “next-generation AI TechBio company” is expected to go public this week. It has attracted a slew of hedge fund investors, including several of the most well-known firms.Caris Life Sciences plans to sell 23,529,412 shares for between $19 and $20 each, according to a regulatory filing. At the higher price, it would raise more than $470 million.

New IPO Alert: Enigmatig Prices $14.2M NYSE American Debut in Cross-Border Solutions Play

Cross-border licensing solutions provider Enigmatig sets $5 IPO price for NYSE American debut. Learn about this unique consultancy's market entry and growth potential.